What do analysts estimate for selpercatinib (Retevmo) peak sales?
Peak sales estimates for selpercatinib vary by forecasting model and assumptions about uptake, line of therapy, pricing, and how quickly competitors enter. In most public market outlooks, the expected peak sales range for selpercatinib is generally reported in the several-hundred–million-to–low–billion USD band, with later peaks driven by broader adoption across RET-mutant NSCLC and RET-altered thyroid cancers, plus mix shift toward earlier settings.
Because no specific figure was provided in the source material available here, I can’t give a single “official” peak-sales number without risking inaccuracy. If you share the forecast source (e.g., an IQVIA, Evaluate, GlobalData, or court/filing excerpt) or the geography (US-only vs. worldwide), I can help you interpret it and reconcile different estimates.
Why do peak-sales forecasts differ so much for selpercatinib?
Forecasts often diverge due to different assumptions about:
- Indication mix and how quickly selpercatinib replaces older RET therapies.
- Share taken from other RET inhibitors and sequencing preferences.
- Pricing and discounting over time (especially post-launch and after payer negotiations).
- Patient eligibility definitions (testing adoption for RET alterations).
- Uptake in thyroid cancer versus NSCLC and the pace of line-of-therapy expansion.
How competing RET drugs affect selpercatinib peak sales
Peak sales can be pressured if a rival captures substantial share (for example, through better tolerability in certain subgroups, physician preference, or broader labeling/real-world use). Conversely, peak sales can be higher if competitors are weaker in specific populations or if expanded biomarker testing grows the addressable market faster than expected.
If you want an exact “peak sales” number, what details should you provide?
To pinpoint a credible peak-sales estimate, it helps to know:
- Forecast publisher (or link/excerpt)
- Forecast horizon and year of peak
- Geography (US, EU5, or global)
- Whether peak sales are net sales or revenue and whether biosimilar/LOE adjustments are included
Share any of those, and I’ll map the numbers cleanly to “peak sales” and explain what drives the forecast.
Sources cited
No sources were provided in the prompt.